INVESTORS CAREERS RESOURCES Filter by BU or service All Corporate Service Biotech A.I Homing program Financial HR Filter by category All Webinar Posters Scientific publications Press release Press coverage Media kit News Scientific resources Webinar Service 16/11/2021 [EN] How Rodent and NHP Models Support COVID-19 Treatment Development Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar Read more Service 05/11/2021 [EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers. Read more Service 04/05/2021 [EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection Read more Service 19/11/2020 [EN] Cancer Vaccine toolbox: innovative strategies for prophylactic or therapeutic vaccines Read more Posters Service 27/09/2021 Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond Read more Service 27/09/2021 Animal models for novel therapies on fibrosis and NASH Read more Service 02/09/2020 Development of an immunogenicity assay for Anti-Drug Antibody (ADA) detection directed against an oligonucleotide CpG D35 using ECL technology (MSD) Service 02/09/2020 mAb formulation development and stability studies through complementary and orthogonal analytical methods Scientific publications Service 04/09/2021 Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2 SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals Read more Service 04/09/2021 Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2 SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat. Read more Biotech 12/06/2021 Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors Read more Service 19/05/2021 Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models Read more Press Press release Biotech 04/11/2021 ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia Read more Corporate Financial 25/10/2021 Oncodesign has appointed Karine Lignel as Group Chief Development Officer Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel. Read more Corporate Financial 25/10/2021 Oncodesign has appointed Karine Lignel as Group Chief Development Officer Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel. Read more Biotech 21/10/2021 Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. Read more Press coverage Financial 29/01/2021 [FR] Biotech Info – Oncodesign, la médecine de précision en ligne de mire Corporate Biotech 26/06/2019 [FR] Oncodesign a peut-être découvert la molécule qui va lui faire retrouver les faveurs de la Bourse Corporate Biotech 26/06/2019 [FR] Oncodesign a peut-être découvert la molécule qui va lui faire retrouver les faveurs de la Bourse Biotech 26/06/2019 [FR] ONCODESIGN atteint une étape déterminante dans le développement de son programme RIPK2 Media kit Corporate MEDIA KIT Find all the media information of Oncodesign, logo, boiler plate, photos, press contacts Read more News Biotech 23/11/2021 Biotech Show Case: looking for partners to pursue the development of our Nanocyclix® technology products together! Meet Dr. Jan Hoflack during Biotech ShowCase to explore our products pipeline using our technological module Nanocyclix®. Read more Biotech 04/11/2021 ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia Read more Corporate A.I 28/10/2021 Oncodesign: EHDEN Certified SME EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline. Read more Contact-us 18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260 Get in touch Science within easy reach! Receive our general letter or our financial news! Explore Oncodesign's vitality Legal notice Personal data policy